MILK COAGULANT AND METHOD FOR PRODUCING CHEESE
This application is based upon and claims priority to Chinese Patent Application No. 201711376336.8, filed on Dec. 19, 2017, the entire content of which is incorporated herein by reference. The present disclosure relates to the food field, particular to a milk coagulant and a method for producing cheese, more particular to a milk coagulant, a method for obtaining asclepain of Asclepias Linn. and cysteine protease B of Calotropis R. Br. and a method of producing cheese. Cheese is a fermented or fresh milk product prepared by curding a raw material (such as, milk, watery cream, partly skimmed milk, buttermilk or their combination) with a milk coagulant like chymosin followed by separating milk serum. The cheese is rich of proteins, fat, vitamins and minerals such as calcium, phosphorus and the like, which is also called as “milk gold”. However, there is still a need to explore the types of milk coagulant. Embodiments of the present disclosure aim at to solve at least one of problems existing in the related art to at least some extent. For this purpose, the present disclosure in embodiments provides a milk coagulant, a method for obtaining asclepain of Asclepias Linn. and cysteine protease B of Calotropis R. Br., as well as a method of producing cheese. According to embodiments of the present disclosure, at least one of the asclepain of Asclepias Linn. and the cysteine protease B of Calotropis R. Br. as the milk coagulant functions on milk clotting under a broad range of temperatures and at a wide range of pH values, as well exhibits great milk-clotting effect, with the cheese obtained in excellent texture and sensory quality. It should be noted that the present disclosure is accomplished by present inventors based on the following findings. Although calf rennet is a chymosin widely used in the manufacture of cheese, the production and application of the calf rennet are limited to many factors. For example, the calf rennet produced by killing a calf is still in short supply due to the increase in cheese demand For another example, the use of animal rennet in cheese production is limited by the diet taboos of religious (such as Judaism, Islam and the like) and vegetarian consumers. In view of the above, it is found by the present inventors that In one aspect, the present disclosure in embodiments provides a milk coagulant. According to embodiments of the present disclosure, the milk coagulant includes at least one of asclepain of Asclepias Linn. and cysteine protease B of Calotropis R. Br. It is surprisingly discovered by the present inventors that the asclepain of Asclepias Linn. and the cysteine protease B of Calotropis R. Br. exhibit milk-clotting effect. With further investigation, it is found by the present inventors that such two proteases function on milk clotting under a broad range of temperatures and at a wide range of pH values, as well exhibit great milk-clotting effect, with the cheese obtained in excellent texture and sensory quality. In embodiments of the present disclosure, the milk coagulant in this aspect also has additional technical features as follows. In embodiments of the present disclosure, the asclepain of Asclepias Linn. and the cysteine protease B of Calotropis R. Br. are from In embodiments of the present disclosure, the milk coagulant further includes at least one of a calcium-containing compound and an aluminum-containing compound, thereby improving milk-clotting activity. In embodiments of the present disclosure, the milk coagulant functions under a temperature of 40° C. to 70° C. and at a pH value of 5.5 to 8.0. It is discovered by the present inventors that the asclepain of Asclepias Linn. and the cysteine protease B of Calotropis R. Br., respectively achieve optimum milk-clotting effects under such the temperature and at the pH value. In embodiments of the present disclosure, the asclepain of Asclepias Linn. is capable of hydrolyzing Ser132-Thr133 peptide linkage on κ-casein. In embodiments of the present disclosure, the cysteine protease B of Calotropis R. Br. is capable of hydrolyzing Asp14-Glu15 peptide linkage and Ser132-Thr133 peptide linkage on κ-casein. In another aspect, the present disclosure in embodiments provides a method for obtaining asclepain of Asclepias Linn. and cysteine protease B of Calotropis R. Br. According to embodiments of the present disclosure, the method includes: soaking leaves of Cynanchum otophyllum Schneid. in a buffer, followed by collecting an extracted solution; and purifying the extracted solution, so as to obtain the asclepain of Asclepias Linn. and the cysteine protease B of Calotropis R. Br., respectively, wherein the asclepain of Asclepias Linn. and the cysteine protease B of Calotropis R. Br. are those in the milk coagulant as defined in the above aspect. With the method of the present disclosure in this aspect, it is possible to extract the asclepain of Asclepias Linn. and the cysteine protease B of Calotropis R. Br. with high purity by effective and simple operations. In embodiments of the present disclosure, the method for obtaining the asclepain of Asclepias Linn. and the cysteine protease B of Calotropis R. Br. in the above aspect also has additional technical features as follows. In embodiments of the present disclosure, the buffer is a citric acid-phosphate buffer, thereby facilitating to dissolve In embodiments of the present disclosure, the citric acid-phosphate buffer is of a concentration of 10 mmol/L, thereby further facilitating to dissolve In embodiments of the present disclosure, the leaves of In embodiments of the present disclosure, the leaves of In embodiments of the present disclosure, purifying the extracted solution further includes: subjecting the extracted solution to ultrafiltration for concentration, thereby obtaining a concentrated solution; and eluting the concentrated solution on a chromatographic column, so as to obtain proteases of In embodiments of the present disclosure, the ultrafiltration for concentration is performed using an ultrafiltration tube in 10.0 kD, thereby further benefiting for separation, purification and acquisition of the asclepain of Asclepias Linn. and the cysteine protease B of Calotropis R. Br. In still another aspect, the present disclosure in embodiments provides a method of producing cheese. According to embodiments of the present disclosure, the method includes: mixing cheese milk with the milk coagulant as defined in above aspects, thereby obtaining a mixture; and keeping the mixture standing for a time period, so as to obtain the cheese. With the method of producing cheese in embodiments of the present disclosure, the cheese obtained is in excellent texture and sensory quality. In embodiments of the present disclosure, the method in this aspect further includes: adjusting the mixture obtained to be at a pH value of 5.5 to 8.0, thus the milk coagulant exhibits optimum milk-clotting effect at such the pH value. In embodiments of the present disclosure, the mixture is kept standing under 40° C. to 70° C. for 40 minutes to 90 minutes, thus the milk coagulant exhibits milk-clotting effect sufficiently under such the temperature. The additional aspects and advantages of the present disclosure will be given partly from the following description, part of which will become apparent from the description or understood from the practice of the present disclosure. The above and/or additional aspects and advantages of the present disclosure will become apparent and easily understood from the description of embodiments in combination with the accompanying drawings, in which: The embodiments of the present disclosure are described in detail below. Such embodiments are explanatory, and aim at to explain the present disclosure rather than to be constructed to limit the present disclosure. The present disclosure provides in embodiments a milk coagulant, a method for obtaining asclepain of Asclepias Linn. and cysteine protease B of Calotropis R. Br., as well as a method of producing cheese, each of which will be described in detail as bellows. For better understanding, milk-clotting mechanism of the milk coagulant is set forth briefly as follows. Milk-clotting reaction is performed in two steps in the presence of the milk coagulant. Specifically, in an initial step, κ-casein is hydrolyzed by the milk coagulant to be non-active and degraded into para-k-casein and glycomacropeptide (i.e. a small peptide which is trichloroacetic acid-dissoluble); subsequently, in a second step, the para-k-casein is gradually aggregated to become a three-dimensional network structure in the presence of adequate calcium ions under a temperature higher than 20° C., thus forming a milk-clot. Milk Coagulant In one aspect, the present disclosure in embodiments provides a milk coagulant. According to embodiments of the present disclosure, the milk coagulant includes at least one of asclepain of Asclepias Linn. and cysteine protease B of Calotropis R. Br. It is surprisingly discovered by the present inventors that the asclepain of Asclepias Linn. and the cysteine protease B of Calotropis R. Br. exhibit milk-clotting effect. With further investigation, it is found by the present inventors that such two proteases function on milk clotting under a broad range of temperatures and at a wide range of pH values, as well exhibit great milk-clotting effect, with the cheese obtained in excellent texture and sensory quality. In embodiments of the present disclosure, the asclepain of Asclepias Linn. (i.e. protease QA in short) and the cysteine protease B of Calotropis R. Br. (i.e. protease QC in short) are from In embodiments of the present disclosure, the milk coagulant further includes at least one of a calcium-containing compound and an aluminum-containing compound. It is discovered by the present inventors that calcium ions and aluminum ions improve the milk-clotting activities of the proteases QA and QC significantly, thus guaranteeing good milk-clotting effect for the QA and QC, for example, reduced milk-clotting time, and the cheese obtained in suitable texture. In embodiments of the present disclosure, the milk coagulant functions under a temperature of 40° C. to 70° C. and at a pH value of 5.5 to 8.0. It is found by the present inventors that the proteases QA and QC exhibit great milk-clotting effect. In embodiments of the present disclosure, the asclepain of Asclepias Linn. is capable of hydrolyzing Ser132-Thr133 peptide linkage on κ-casein; and the cysteine protease B of Calotropis R. Br. is capable of hydrolyzing Asp14-Glu15 peptide linkage and Ser132-Thr133 peptide linkage on κ-casein. Both the asclepain of Asclepias Linn. and the cysteine protease B of Calotropis R. Br. are able to hydrolyze α-casein, β-casein and κ-casein. It is found by the present inventors unexpected that the cleavage sites of the proteases QA and QC of the present disclosure differ from that of the calf rennet, because the cleavage site of the calf rennet on κ-casein is Phe105-Met106 peptide linkage. Method for Obtaining Asclepain of Asclepias Linn. and Cysteine Protease B of Calotropis R. Br. In another aspect, the present disclosure in embodiments provides a method for obtaining asclepain of Asclepias Linn. and cysteine protease B of Calotropis R. Br., respectively. With the method in embodiments of the present disclosure, it is possible to extract the asclepain of Asclepias Linn. and the cysteine protease B of Calotropis R. Br. with high purity by effective and simple operations. Referring to S100 Soaking In the step S100, leaves of In embodiments of the present disclosure, the buffer is a citric acid-phosphate buffer. It is discovered by the present inventors that the proteases QA and QC exhibit high solubility in the citric acid-phosphate buffer among various buffers. Further, the In embodiments of the present disclosure, the leaves of It should be noted that term “a ratio of mass to volume” in this context refers to the ratio of the mass of In embodiments of the present disclosure, the leaves of S200 purification In the step S200, the extracted solution is purified, so as to obtain the asclepain of Asclepias Linn. and the cysteine protease B of Calotropis R. Br. Referring to S210 Ultrafiltration for concentration In the step S210, the extracted solution is subjected to ultrafiltration for concentration, thereby obtaining a concentrated solution. In embodiments of the present disclosure, the ultrafiltration for concentration is performed using an ultrafiltration tube in 10.0 kD. It is found by the present inventors that a concentrated solution obtained by concentrating the extracted solution with the ultrafiltration tube in 10.0 kD contains proteins in a significant increased concentration, as well exhibits as three main bands in distinct molecule weights between 6.5 kD and 27.0 kD evidenced by the SDS-PAGE electrophoresis; while the filtered solution contains barely proteins. It is demonstrated that the proteases included in the extracted solution of S220 Elution In the step S220, the concentrated solution is eluted on a chromatographic column, so as to obtain proteases of In embodiments of the present disclosure, eluting the concentrated solution further includes steps of: 1) loading the concentrated solution onto the chromatographic column and collecting a first outflow, so as to obtain the asclepain of Asclepias Linn.; 2) loading a citric acid-phosphate buffer onto the chromatographic column obtained in step 1), with a second outflow obtained; and 3) loading a citric acid-phosphate buffer containing 0.6 mmol/L NaCl onto the chromatographic column obtained in step 2), and collecting a third outflow, so as to obtain the cysteine protease B of Calotropis R. Br. It is found by the present inventors that the protease QA directly flows out rather than being absorbed onto the chromatographic column after the concentrated solution is loaded onto the chromatographic column, thereby obtaining the protease QA by collection of the first outflow; subsequently, the column is eluted with a citric acid-phosphate buffer without NaCl, thereby obtaining another In embodiments of the present disclosure, the asclepain of Asclepias Linn. and the cysteine protease B of Calotropis R. Br. are those in the milk coagulant as defined in the above aspects. It should be understood by those skilled in the art that the features and advantages of the milk coagulant described above are also suitable for this method in embodiments, which will not be described again in detail. Method of producing cheese In still another aspect, the present disclosure in embodiments provides a method of producing cheese. According to embodiments of the present disclosure, the method includes: mixing cheese milk with the milk coagulant as defined in above aspects, thereby obtaining a mixture; and keeping the mixture standing for a time period, so as to obtain the cheese. As described above, the milk coagulant in embodiments of the present disclosure functions on milk clotting under a broad range of temperatures and at a wide range of pH values, as well exhibits great milk-clotting effect, with the cheese obtained in excellent texture and sensory quality. It should be understood by the present inventors that term “cheese milk” in this context mainly refers to a raw material to be clotted. In embodiments of the present disclosure, the method further includes: adjusting the mixture obtained to a pH value of 5.5 to 8.0. With adjustment of such the mixture obtained by mixing the cheese milk with the milk coagulant to be at an optimum pH value for milk-clotting (i.e. 5.5 to 8.0), it is beneficial for the milk coagulant to exhibit milk-clotting effect, thus obtaining cheese in excellent texture and sensory quality. In embodiments of the present disclosure, the mixture is kept standing under 40° C. to 70° C. for 40 minutes to 90 minutes. With mixture standing under such the condition, it is beneficial for the milk coagulant to exhibit milk-clotting effect, thus obtaining cheese in excellent texture and sensory quality. It should be understood by those skilled in the art that the features and advantages of the milk coagulant described above are also suitable for this method of producing cheese in embodiments, which will not be described again in detail. Reference will be made in detail to examples of the present disclosure. It would be appreciated by those skilled in the art that the following examples are explanatory, and cannot be construed to limit the scope of the present disclosure. If the specific technology or conditions are not specified in the examples, a step will be performed in accordance with the techniques or conditions described in the literature in the art or in accordance with the product instructions. If the manufacturers of reagents or instruments are not specified, the reagents or instruments may be commercially available. General procedure 1. Samples and Reagents Samples of 2. The protein concentrations of 4 partially purified protease extracted solutions were measured following the method of Bradford (1976) with Coomassie Brilliant Blue, where bovine serum albumin (BSA) was used as a protein standard. 3. Milk Clotting Activity Assay The MCA of the MCA =2400xV/ (vxt) where V stands for the volume of the substrate (mL); v stands for the volume of the protease extract; and t stands for the milk-clotting time (s). 4. Caseinolytic Activity Assay The caseinolytic activities of the 5. Kinetics Analysis of the κ-Casein by the Proteases The hydrolysis kinetics of κ-casein by the proteases was evaluated as described by Nafi' et al. (2014) with some modifications. Five mg/mL of κ-casein stock solutions was dissolved in 10 mM citric acid-phosphate buffer (pH 6.5), then diluted with the buffer to concentrations of 0.1, 0.5, 1.0, 1.5, and 2.0 mg/mL. The diluted solutions were first incubated under 37° C. for 5 min, then the proteases were added at a ratio of 1 to 10 (vol/vol). After reacting for 10 min, the same volume of 5% (wt/vol) TCA was immediately added to terminate the reaction. The kinetic parameters, Michaelis constant (Km), catalytic turnover number (kcat), and proteolytic coefficient (kcat/Km), were calculated using the Lineweaver-Burk plot (Lineweaver and Burk, 1934). 6. Hydrolysis of Casein The level of casein hydrolysis was determined as described by Huang et al. (2011). Bovine α-casein, β-casein, and κ-casein (50 mg each) were prepared separately by dissolving them in 10 mL of 10 mmol/L of citric acidphosphate buffer (pH 6.5). The proteases were added to each substrate at a ratio of 1:10 then hydrolyzed at 65° C. for 5, 15, and 30 min and 1, 2, and 4 h. The degree of degradation was analyzed using SDS-PAGE. 7. Statistical Analyses All measurements were performed in triplicate. The data were analyzed by 1-way ANOVA (with Duncan's multiple range method) or the t-test using SPSS software (version 22.0, IBM, Armonk, N.Y.). The level for statistical significance was set at P<0.05. Example 1 Basic Extraction The 1. Extraction Condition Three aliquots of the 2. Solid-Liquid Ratios The 3. Buffers The 4. Separation and purification Ultrafiltration is a technology for separation of materials in different sizes by means of an ultrafiltration membrane. Generally, the material in a size less than the membrane pore size will pass through the membrane, while in contrast the material in a size above the membrane pore size will be cut off. Therefore, the ultrafiltration process enables to improve concentration of proteases in the extracted solution, as well to remove impurities (for example, some small molecules, such as phenols and pigments) in the extracted solution. The concentrated solution of Table 4 shows the optical density at 280 nm, protein content and milk-clotting activity of the individual fractions. The results of the optical density at 280 nm and protein content show that the proteases are mainly concentrated in QA and QC fractions after purification of the concentrated solution derived by ultrafiltration with the weak anion exchange resins. From the results of curd formation time, only the QA and QC fractions enable the milk to clot. Example 2 Basic characteristics of proteases QA and QC Milk-Clotting Activity and Proteolytic Activity Milk-clotting activity and proteolytic activity are very important properties for application of a milk coagulant. In addition to MCA, PA plays a critical role in evaluating the suitability of a milk-clotting enzyme. Proteolysis strongly affects the degradation patterns of caseins, which could further affect the yield and sensory properties of the cheese. Therefore an enzyme with a high MCA and low PA is preferred (Shah et al., 2014). Table 5 shows that the ratios of MCA/PA for QA and QC were 37.33 and 36.14, respectively, significantly higher values than those of purified enzymes from Onopordum acanthium (9.58), Bromelia hieronymi (4.18), and Philibertia gilliesii (4.82; Brutti et al., 2012). Usually, the ratio of milk-clotting activity to proteolytic activity is a measurement for estimating whether the milk coagulant is suitable for cheese production. Higher the ratio often indicates more suitable the milk coagulant for the cheese production. As seen in Table 6, the ratios of milk-clotting activity to proteolytic activity of rennet derived from plants (such as Onopordum acanthium, Cynara cardunculus, Asclepias fruticosa, Bromeliaceae and the like) are all below 10.0, specifically the ratio of milk-clotting activity to proteolytic activity of Asclepias fruticosa is just 0.68, showing that all of these ratios are far lower than those of QA and QC (respectively, 37.37 and 36.14). Thus, the Kinetic Parameters of κ-Casein by the Proteases QA and QC The higher proteolytic efficiency of chymosin on κ-casein, the faster generation of hydrophobic N-terminal moiety of κ-casein, the faster the aggregation rate of casein micelles (Shammet et al., 1992). Therefore, evaluation of kinetic parameters of the Identification of the Proteases QA and QC The purified Specificity of the Proteases QA and QC on the Hydrolysis of Types of Casein Example 3 Effect on Enzymatic Property—proteolytic activity 1. pH value A variation of pH in the system can affect the dissociation of the dissociable groups in the active center and thus affect the proteolytic activity (Shah et al., 2014). The effect of pH on the PA of the As milk has a natural pH of 6.5 to 6.7 and the coagulation of milk cake is usually performed at a pH of 5.5 to 6.0, the fact that 2. Temperature The effect of temperature on the PA of the The pH and temperature profiles were similar to those of the milk clotting enzymes from C. trigonus Roxburghi and S. dubium (Asif-Ullah et al., 2006; Ahmed et al., 2009). 3. Protease Inhibitor The type of protease was determined as described by Mazorra-Manzano et al. (2013) with modification.Different protease inhibitors (8 mmol/L, 0.1 mL), a serine protease (phenylmethylsulfonyl fluoride, PMSF), a cysteine protease [transepoxy-succinylleucyl-amido-(4-guanidino)-butane, E-64], a metallo protease (EDTA), and an aspartic protease (pepstatin A), were added to 1 mL of the proteases. The mixtures were incubated at 37° C. for 30 min, then PA was evaluated. The percentage inhibition was calculated as follows: Compared to the control, the activity of QA and QC was also inhibited by serine protease Phenylmethylsulfonyl fluoride (PMSF), by showing about 15% reduction in the activity ( In view of the above, it is indicated that the Example 4 Effect on Enzymatic Property—milk-clotting activity 1. pH 2. Temperature The temperature also has a significant influence on Heating may have denatured the whey proteins to form a complex of κ-casein with whey protein, which decreased the effective κ-casein concentration in the substrate and thus increased the curding time (Horne and Banks, 2004). The optimum temperature observed in the 3. Metal Ion Some metal ions as a cofactor can participate in the milk-clotting reaction, thus affecting activity of enzyme. Further, the skim milk is of increased iron strength after addition of salts, thus interfering the stability of casein micelle and the formation of the milk clot. Example 5 Analysis of the Cleavage Site on x-Casein by the Proteases The cleavage site on κ-casein used by the proteases was determined as described by Zhang et al. (2015) with some modifications. The κ-casein solution was prepared in 10 mmol/L of citric acid-phosphate buffer (pH 6.5) at a concentration of 5 mg/mL. The After 1 h of incubation, the κ-casein hydrolysate was excised from the gel to determine the cleavage site on κ-casein by the In the specification of the present disclosure, the terms “an embodiment”, “some embodiments”, “an example”, “a specific example”, “some examples” or “a particular embodiment” and the like are intended to refer to particular features, structures, materials or characteristics described by way of example or embodiment are contained in at least one embodiment or example of the disclosure. In this specification, the schematic representation of the above terms does not necessarily refer to the same embodiment or example Moreover, the particular features, structures, materials or characteristics described may be combined in any suitable manner in one or more embodiments or examples. In addition, various embodiments or examples described in the specification, as well as features of such the embodiments or examples, may be combined by those skilled in the art without conflict. Although embodiments of the present disclosure have been described, it will be understood by those skilled in the art that such the embodiments are explanatory and should not be construed to limiting the present disclosure. Further, various changes, modifications, substitutions and variations can be made in these embodiments by those skilled in the art without departing from the scope of the present disclosure. 1. Ahmed, I. A. M., I. Morishima, E. E. Babiker, and N. Mori. 2009. Dubiumin, a chymotrypsin-like serine protease from the seeds of 2. Asif-Ullah, M., K.-S. Kim, and Y. G. Yu. 2006. Purification and characterization of a serine protease from 3. Bruno, M. A., C. M. Lazza, M. E. Errasti, L. M. I. Lopez, N. 0. Caffini, and M. F. Pardo. 2010. Milk clotting and proteolytic activity of an enzyme preparation from Bromelia hieronymi fruits. Lebensm. Wiss. Technol. 43:695-701. 4. Brutti, C. B., M. F. Pardo, N. 0. Caffini, and C. L. Natalucci. 2012. Onopordum acanthium L. ( 5. Demir, Y., A. A. Gungor, E. D. Duran, and N. Demir. 2008. Cysteine protease (capparin) from capsules of caper (Capparis spinosa). Food Technol. Biotechnol. 46:286-291. 6. Egito, A. S., J. M. Girardet, L. E. Laguna, C. Poirson, D. Mollé, L. Miclo, G Humbert, and J. L. Gaillard. 2007. Milk-clotting activity of enzyme extracts from sunflower and albizia seeds and specific hydrolysis of bovine x-casein. Int. Dairy J. 17:816-825. 7. He, X., F. Ren, H. Guo, W. Zhang, X. Song, and B. Gan. 2011. Purification and properties of a milk-clotting enzyme produced by 8. Huang, X. W., L. J. Chen, Y. B. Luo, H. Y. Guo, and F. Z. Ren. 2011. Purification, characterization, and milk coagulating properties of ginger proteases. J. Dairy Sci. 94:2259-2269. 9. Lineweaver, H., and D. Burk. 1934. The determination of enzyme dissociation constants. J. Am. Chem. Soc. 56:658-666. 10. Lo Piero, A. R., I. Puglisi, and G Petrone. 2002. Characterization of “lettucine,” a serine-like protease from 11. Lo Piero, A. R., I. Puglisi, and G Petrone. 2011. Characterization of the purified actinidin as a plant coagulant of bovine milk. Eur. Food Res. Technol. 233:517-524. 12. Mazorra-Manzano, M. A., T. C. Perea-Gutierrez, M. E. Lugo-Sanchez, J. C. Ramirez-Suarez, M. J. Torres-Llanez, A. F. Gonzalez-Cordova, and B. Vallejo-Cordoba. 2013. Comparison of the milk-clotting properties of three plant extracts. Food Chem. 141:1902-1907. 13. Mohanty, A. K., K. Mukhopadhyay, J. K. Kaushik, S. Grover, and V. K. Batish. 2003. Isolation, purification and characterization of chymosin from riverine buffalo ( 14. Nafi', A., H. L. Foo, B. Jamilah, and H. M. Ghazali. 2013. Properties of proteolytic enzyme from ginger ( 15. Nafi', A., F. H. Ling, J. Bakar, and H. M. Ghazali. 2014. Partial characterization of an enzymatic extract from Bentong ginger ( 16. Parisi, M., S. Moren, and G Fernandez. 2002. Characterization of a novel cysteine peptidase from tissue culture of garlic ( 17. Shah, M. A., S. A. Mir, and M. A. Paray. 2014. Plant proteases as milk-clotting enzymes in cheesemaking: A review. Dairy Sci. Technol. 94:5-16. 18. Shammet, K. M., R. J. Brown, and D. J. McMahon. 1992. Proteolytic activity of some milk-clotting enzymes on x-casein. J. Dairy Sci. 75:1373-1379. 19. Sharma, A., M. Kumari, and M. Jagannadham. 2012. Religiosin C, a cucumisin-like serine protease from 20. Vreeman, H. J., S. Visser, C. J. Slangen, and J. Van Riel. 1986. Characterization of bovine lc-casein fractions and the kinetics of chymosin-induced macropeptide release from carbohydrate-free and carbohydrate-containing fractions determined by high-performance gel-permeation chromatography. Biochem. J. 240:87-97. 21. Zhang, Y., H. Wang, L. Tao, and A.-X. Huang. 2015. Milk-clotting mechanism of Provided in the present disclosure are a milk coagulant, a method for obtaining asclepain of Asclepias Linn. and cysteine protease B of Calotropis R. Br., as well as a method of producing cheese. The milk coagulant includes at least one of the asclepain of Asclepias Linn. and the cysteine protease B of Calotropis R. Br. 1. A milk coagulant, comprising at least one of asclepain of Asclepias Linn. and cysteine protease B of Calotropis R. Br. 2. The milk coagulant according to 3. The milk coagulant according to 4. The milk coagulant according to 5. The milk coagulant according to 6. The milk coagulant according to 7. The milk coagulant according to 8. A method for obtaining asclepain of Asclepias Linn. and cysteine protease B of Calotropis R. Br., comprising:
soaking leaves of purifying the extracted solution, so as to obtain the asclepain of Asclepias Linn. and the cysteine protease B of Calotropis R. Br., respectively, wherein the asclepain of Asclepias Linn. and the cysteine protease B of Calotropis R. Br. are those in the milk coagulant as defined in 9. The method according to 10. The method according to 11. The method according to 12. The method according to 13. The method according to 14. The method according to 15. The method according to subjecting the extracted solution to ultrafiltration for concentration, thereby obtaining a concentrated solution; and eluting the concentrated solution on a chromatographic column, so as to obtain proteases of eluting the concentrated solution further comprises steps of: 1) loading the concentrated solution onto the chromatographic column and collecting a first outflow, so as to obtain the asclepain of Asclepias Linn.; 2) loading a citric acid-phosphate buffer onto the chromatographic column obtained in step 1), with a second outflow obtained; and 3) loading a citric acid-phosphate buffer containing 0.6 mmol/L NaCl onto the chromatographic column obtained in step 2), and collecting a third outflow, so as to obtain the cysteine protease B of Calotropis R. Br. 16. The method according to 17. A method of producing cheese, comprising:
mixing cheese milk with the milk coagulant as defined in keeping the mixture standing for a time period, so as to obtain the cheese. 18. The method according to adjusting the mixture obtained to a pH value of 5.5 to 8.0; and keeping the mixture standing at 40° C. to 70° C. for 40 minutes to 90 minutes.CROSS-REFERENCE TO RELATED APPLICATIONS
FIELD
BACKGROUND
SUMMARY
BRIEF DESCRIPTION OF THE DRAWINGS
DETAILED DESCRIPTION
Effect of different extraction conditions on extraction of proteases of Different treatment temperatures Milk-clotting time (min) treatment at 55° C. for 40 minutes 110 minutes treatment at 25° C. for 40 minutes 40 minutes treatment at 4° C. for 40 minutes 15 minutes Effect of different solid-liquid ratios on extraction of proteases of Solid-liquid ratio Milk-clottting activity (U/mg) 1:10 147.7 1:20 213.6 1:30 204.2 Effect of different buffers on extraction of proteases of Protein Milk-clotting Different buffers content (mg/mL) activity (U/mg) ultrapure water 0.136 198.1 citric acid-phosphate buffer 0.305 201.5 (pH 6.5, 10 mmol/L) Identification of purified fractions of Protein Fraction A280 content (mg/ml) curd formation time QA 0.382 0.189 milk-clotting within 35 minutes QB 0.106 0.031 no milk-clotting within 4 hours QC 0.425 0.155 milk-clotting within 50 minutes QD 0.129 0.072 no milk-clotting within 4 hours Milk-clotting activity and proteolytic activity of Milk-clotting Proteolytic Proteases activity (U/mg) activity (SU/mg) MCA/PA QA 332.6 ± 1.9b 8.91 ± 0.14b 37.33 QC 267.4 ± 2.7a 7.40 ± 0.21a 36.14 a,bMeans in a column with different superscripts are significantly different (P < 0.05). Results are mean ± SD (n = 3). SU = Soxhlet unit. Milk-clotting activity and proteolytic activity of rennet from other plants ratio of Milk- Milk-clotting Proteolytic clotting activity activity activity to proteolytic Type of plant rennet (U/mL) (SU/mL) activity 0.546 ± 0.004 0.019 ± 0.002 9.58 103.6 ± 4.1 16.4 ± 1.3 5.34 0.7 ± 0.02 1.03 ± 0.06 0.68 6.85 ± 0.3 1.32 ± 0.03 5.19 10.0 ± 0.005 2.39 ± 0.04 4.18 16.0 ± 0.003 3.32 ± 0.03 4.82 Kinetic parameters of Schneid. proteases QA and QC1. Proteases QA QC Km(mg/mL) 0.397 ± 0.002a 1.708 ± 0.014b kcat(min) 99.65 ± 2.32b 83.61 ± 1.46a kcat./Km[mL/(mg · min)] 251.01 ± 6.11b 48.95 ± 1.93a a-bMeans in a column with different superscripts are significantly different (P < 0.05). 1Results are mean ± SD (n = 3). Michaelis constant (Km), catalytic turnover number (Kcat), and proteolytic coefficient (kcat/Km). Identification results of Accession Protein Sequence Molecular proteases numbera Protein nameb Plant sourcec scored coveragee weightf QA gi|215414308 asclepain cI 150.73 11.3% 21.3 kD gi|215414310 asclepain cII 93.46 7.3% 20.9 kD QC gi|615503249 procerain B 267.53 53.4% 36.4 kD gi|475638275 procerain B, 286.56 53.3% 23.8 kD partial Noted: aAccession number in NCBI data bank; bProtein name obtained from NCBI data bank; cSource of the protein from NCBI data bank; dmolecular weight searching score of protein; eSequence coverage of identified protein; ftheoretical molecular weight from Uniprot.
percentage inhibition=100−[100−(residual activity/activity without inhibitor)].Identification of peptide sequences of in-gel digested product of peptide segments from κ-casein by Molecular weight of peptide (Da) Observed Peptide Protease Score Peptide sequence ([M + H]+)1 Calculated origin QA 729.38 SPAQILQWQVLSNTVPAK (SEQ ID NO: 1) 1980.08 1979.08 κ-casein (69-86) SCQAQPTTMAR (SEQ ID NO: 2) 1192.56 1192.53 κ-casein (87-97) HPHPHLSFMAIPPK (SEQ ID NO: 3) 1608.85 1607.84 κ-casein (98-111) NQDKTEIPTINTIASGEPTS (SEQ ID NO: 4) 2116.04 2115.03 κ-casein (113-132) QC 988.79 PAAVRSPAQILQWQVLSNTVPAKSCQAQP 3648.94 3647.90 κ-casein TTMAR (SEQ ID NO:5) (63-97) HPHPHLSFMAIPPK (SEQ ID NO: 6) 1608.84 1607.84 κ-casein (98-111) NQDKTEIPTINTIASGEPTS (SEQ ID NO: 7) 2116.04 2115.03 κ-casein (113-132) gi | 162811 κ-casein precursor ( 1[M + H]+indicates the mass and the charge of the molecular ions. REFERENCES









